Loading
Cholangiocarcinoma and Gallbladder Cancer Studies / Liver Diseases and Immunity · Journal article
Frontiers in Pharmacology · September 7, 2026
A consensus or society position rather than new primary data.
This review consolidates evidence that chemoimmunotherapy with checkpoint inhibitors (TOPAZ-1, KEYNOTE-966) has replaced chemotherapy alone as first-line treatment for advanced biliary tract cancer, but notes that only a minority achieve durable benefit. Conventional biomarkers (mismatch repair deficiency, microsatellite instability, tumor mutational burden, PD-L1) have limited predictive value in BTC due to intratumoral heterogeneity; emerging composite models and investigational cellular therapies (CAR-T, TIL therapy, therapeutic vaccines) are under study but require validation.
Journal article. Patients with advanced (unresectable or metastatic) biliary tract cancer.
Phase 3 TOPAZ-1 and KEYNOTE-966 trials established chemoimmunotherapy with immune checkpoint inhibitors as new first-line standard for advanced BTC Phase 2 IMbrave151 trial is evaluating whether adding antiangiogenic therapy to chemoimmunotherapy provides further benefit Only a minority of patients derive durable clinical benefit from immunotherapy in BTC
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize chemoimmunotherapy as the established first-line regimen for advanced BTC based on phase 3 evidence. However, conventional biomarkers poorly predict response, indicating a clinical need for improved patient stratification tools and combination strategies to improve durable benefit rates.
A narrative review synthesizing current evidence on immunotherapy in advanced biliary tract cancer, highlighting established standards (TOPAZ-1, KEYNOTE-966), emerging biomarkers, and investigational approaches rather than reporting original trial results.
Clinicians should recognize chemoimmunotherapy as the established first-line regimen for advanced BTC based on phase 3 evidence. However, conventional biomarkers poorly predict response, indicating a clinical need for improved patient stratification tools and combination strategies to improve durable benefit rates.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Biliary tract cancers (BTCs) are aggressive, molecularly heterogeneous malignancies, and most patients present with unresectable or metastatic disease at diagnosis. For more than a decade, gemcitabine–platinum chemotherapy served as the first-line standard of care, with only modest survival benefit. The phase 3 TOPAZ-1 and KEYNOTE-966 trials have now established chemoimmunotherapy with immune checkpoint inhibitors as the new standard front-line regimen, and the phase 2 IMbrave151 trial is evaluating whether adding antiangiogenic therapy provides further benefit. Nonetheless, only a minority of patients derive durable clinical benefit from immunotherapy. Conventional predictive biomarkers—deficient mismatch repair or high microsatellite instability, tumor mutational burden, and PD-L1 expression—have limited discriminatory value in BTC, largely because of profound intratumoral heterogeneity. Emerging biomarkers and composite multi-feature models show greater promise for refining patient stratification. Investigational modalities, including therapeutic cancer vaccines, chimeric antigen receptor T cells, and tumor-infiltrating lymphocyte therapy, have shown preliminary antitumor activity but require validation in larger cohorts. Multiple combination regimens aimed at reversing the immunosuppressive tumor microenvironment are under active investigation, and disease-specific protocols for managing hepatobiliary immune-related adverse events remain an unmet clinical need. In this review, we synthesize the latest evidence on biomarkers, clinical trials, combination strategies, cellular therapies, and safety management for immunotherapy in advanced BTC, and we highlight persistent challenges and future research directions.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.